Marie Bleakley
Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marie Bleakley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03970096 · Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)Fred Hutchinson Cancer Center · recruiting · Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia · principal investigator
- Ph2NCT03779854 · Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell TransplantFred Hutchinson Cancer Center · active not recruiting · Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage · principal investigator
- Ph2NCT02220985 · Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDFred Hutchinson Cancer Center · completed · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage · principal investigator
- Ph2NCT01858740 · Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenFred Hutchinson Cancer Center · completed · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage · principal investigator
- Ph2NCT00914940 · Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDFred Hutchinson Cancer Center · terminated · Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer ImmunologyP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2023 to 2026 · $401,412 awarded in 2026Grant number is on one of their registry trials
- Development of Innovative Resources to Advance MDS ResearchRC2DK127989 · NIDDK · FRED HUTCHINSON CANCER CENTER · fiscal years 2023 to 2026 · $1,574,993 awarded in 2026Same name and institution; not confirmed by an ID
- Prevention of Graft-Versus-Host-Disease in the Era of Adoptive ImmunotherapyP01CA018029 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2018 to 2022 · $885,028 awarded in 2022Grant number is on one of their registry trials
- Naive T cell depletion to prevent graft-versus-host diseaseR01HL121568 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2014 to 2018 · $539,649 awarded in 2018Grant number is on one of their registry trials
- Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemiK23CA154532 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2011 to 2015 · $170,100 awarded in 2015Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:45 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed